The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 1-2, 2010, Pages 11-18

  Kaczmarek, Przemysław ^a   Sładek, Krzysztof ^a   Skucha, Wojciech ^b   Rzeszutko, Marcin ^a   Iwaniec, Teresa ^a   Dziedzina, Sylwia ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Regional Hospital   (Poland)

Author keywords

Chronic obstructive pulmonary disease; Inflammation; Simvastatin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GELATINASE B; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT DURATION;

EID: 77649257891     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.869     Document Type: Article

References (39)

1. Global initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2006). http://www.goldcopd.org.
2. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977; 1: 1645-1658.
3. Burrows B, Knudson RJ, Cline MG, et al. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977; 115: 195-205.
4. Matheson MC, Benke G, Raven J, et al. Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax. 2005; 60: 645-651.
5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22: 672-688.
6. Barnes PJ. Alveolar macrophages as orchestrators of COPD, COPD. 2004; 1: 59-70.
7. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J. 2001; 18: 50S-59S.
8. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004; 56: 515-548.
9. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest. 2002; 121: 151S-155S.
10. Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax. 2001; 56: 432-437.
11. Burnett D, Hill SL, Chamba A, Stockley RA. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet. 1987; 2: 1043-1046.
12. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567-572.
13. Rosengren A, Wilhelmsen L. Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int J Epidemiol. 1998; 27: 962-969.
14. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000; 118: 656-664.
15. Engstrom G, Hedblad B, Janzon L, et al. Respiratory decline in smokers and ex-smokers - an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk. 2000; 7: 267-272.
16. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107: 1514-1519.
17. Jantzen F, Könemann S, Wolff B, et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J Physiol Pharmacol. 2007; 58: 503-514.
18. Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005; 25: 1231-1236.
19. Undas A, Topór-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn. 2009; 119: 461-468.
20. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005; 25: 287-294.
21. Undas A, Brożek J, Musiał J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin lab. 2002; 48: 287-296.
22. Ishida W, Kajiwara T, Ishii M, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med. 2007; 212: 265-273.
23. Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007; 29: 279-283.
24. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006; 47: 2554-2560.
25. lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005; 172: 987-993.
26. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002; 166: 1403-1408.
27. Garrod R, Marshall J, Barley E, et al. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J. 2007; 16: 236-240.
28. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59: 574-580.
29. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008; 101: 530-535.
30. Undas A, Celińska-Löwenhoff M, Kaczor M, Musiał J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004; 91: 1065-1077.
31. Polosa R, Cacciola RR, Prosperini G, et al. Endothelial-coagulative activation during chronic obstructive pulmonary disease exacerbations. Haematologica. 2008; 93: 1275-1276.
32. Blamoun Al, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008; 62: 1373-1378.
33. Alessandri C, Basili S, Violi F, et al. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost. 1994; 72: 343-346.
34. Ferroni P, Basili S, Alessandri C, et al. Proinflammatory cytokines and hemostatic system in patients with chronic obstructive pulmonary disease. Platelets. 1997; 8: 255-259.
35. Undas A, Kaczmarek P, Sładek K, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost. 2009; 102: 1176-1182.
36. Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003; 46: 28S-32S.
37. Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001; 163: 737-744.
38. Nishimoto-Hazuku A, Hirase T, Ide N, et al. Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1-alpha upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008; 51: 267-273.
39. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003; 285: H938-H945.